Adcirca (tadalafil) helps improve exercise capacity and reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD). It achieves this by relaxing and widening blood vessels in the lungs, reducing blood pressure in the pulmonary arteries. This increased blood flow improves oxygen delivery to the body.
Understanding Adcirca’s Mechanism
Adcirca works by inhibiting phosphodiesterase-5 (PDE5), an enzyme that breaks down cyclic GMP, a substance that promotes blood vessel relaxation. By blocking PDE5, Adcirca increases cyclic GMP levels, leading to vasodilation. This mechanism is distinct from other PAH therapies, offering a different approach to treatment.
Dosage and Administration
Typical Adcirca dosages for PAH range from 20mg to 40mg once daily. Always follow your doctor’s prescribed dosage and instructions carefully. The medication is taken orally with or without food. Regular monitoring by your physician is vital to assess treatment response and adjust the dose as needed.
